|
|
|
|
|
by mdevere
87 days ago
|
|
Very strange how HN elevates news about random drug candidates at very early stages of development. There is a very active landscape of people developing/validating 'biomarkers' for neurological and psychiatric disorders and developing drugs specifically for those populations with the biomarker present; this news is far from extraordinary. The real news is when these reach FDA approval. |
|